Medicare Drug Pricing Negotiations: Assessing Constitutional Structural Limits.

Area of Science:

• Health Law and Policy
• Administrative Law
• Constitutional Law

Background:

• The Centers for Medicare and Medicaid Services (CMS) is a federal agency overseeing major health programs.
• The Inflation Reduction Act of 2022 granted CMS new authority to negotiate prescription drug prices.
• This authority has faced numerous legal challenges based on constitutional grounds.

Purpose of the Study:

• To analyze the structural constitutional arguments presented in legal cases challenging CMS drug price negotiation powers.
• To assess the potential impact of these arguments on the legitimacy of CMS programs and federal agency authority.
• To examine the implications for the broader administrative state.

Main Methods:

• Review of legal filings and court documents in cases challenging CMS drug price negotiation authority.
• Analysis of constitutional law principles, including separation of powers and non-delegation doctrines.
• Examination of administrative law precedents related to agency powers and statutory interpretation.

Main Results:

• Multiple lawsuits have been filed, raising structural constitutional objections to CMS's authority.
• Arguments often center on the scope of executive branch power and the delegation of authority to administrative agencies.
• The outcomes of these cases could significantly impact the future of federal agency powers and regulatory functions.

Conclusions:

• The legal challenges pose a significant threat to the established authorities of CMS and other federal agencies.
• The resolution of these cases will have far-reaching implications for healthcare policy and the balance of power between Congress, the executive branch, and the judiciary.
• Upholding CMS's authority is crucial for the effective implementation of healthcare legislation aimed at controlling drug costs.